Overview: Parvovirus B19 IgG TestIntroduction: The Parvovirus B19 IgG Test detects Parvovirus B19 IgG to confirm past infection, preventing rash or anemia. Following 2023 IDSA guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, risk assessment, and improving outcomes in immunology for patients with suspected past parvovirus B19 infection, particularly in pregnant women or immunocompromised individuals.
Other Names: Parvovirus IgG Assay, B19 Past Infection Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Parvovirus B19 antibody testing began in the 1980s with viral discovery. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Parvovirus B19 IgG to confirm past infection, guides risk assessment, and prevents rash or anemia.
Test Parameters: 1. Parvovirus B19 IgG Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of rash, anemia, or parvovirus exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document rash, anemia, or history of parvovirus exposure. Include current medications, especially in pregnancy or immunosuppression.
Consent: Written consent required, detailing the tests purpose, parvovirus infection implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect Parvovirus B19 IgG. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for past infection confirmation.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other viruses may reduce specificity.
Clinical Significance: Positive IgG confirms past infection, indicating immunity. Negative results may require IgM testing for recent infection.
Specialist Consultation: Consult an infectious disease specialist or obstetrician for result interpretation and risk assessment.
Additional Supporting Tests: Parvovirus B19 IgM, PCR, or fetal ultrasound to assess parvovirus infection risk.
Test Limitations: Non-specific for active infection; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Parvovirus Guidelines, 2023; Clinical Infectious Diseases, Young NS, 2022.
